Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka’s PDE4 Inhibitor Difamilast Delivers Positive Data for Atopic Dermatitis in Japan PIII
Otsuka Pharmaceutical’s phosphodiesterase 4 (PDE4) inhibitor difamilast (OPA-15406) has demonstrated positive top-line results in two Japan PIII clinical studies in patients with atopic dermatitis, which enrolled adult and pediatric patients, respectively, the company said on March 26. The two PIII…
To read the full story
Related Article
- Otsuka Files Japan NDA for Atopic Dermatitis Drug Difamilast
September 29, 2020
BUSINESS
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
- Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
August 26, 2026
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…